Ozmosi | Onabotulinumtoxina Drug Profile

Product Description

OnabotulinumtoxinA (Botox®; a formulation of botulinum toxin type A (BoNT/A)] is indicated for the prevention of headaches in adults with chronic migraine (CM) in numerous countries, including those of Europe. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33314008/)

Mechanisms of Action: SNAP-25 Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intramuscular

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Onabotulinumtoxina

Countries in Clinic: Austria, Belgium, Bulgaria, Canada, China, Czech Republic, France, Georgia, Germany, Hungary, Italy, Japan, Korea, Latvia, Netherlands, Poland, Russia, Slovakia, Spain, Switzerland, Taiwan, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 65

Recent & Upcoming Milestones

Clinical Outcomes Reported - AbbVie presented P2 Tremor results on 2025-10-06 for Onabotulinumtoxina

Highest Development Phases

Phase 1: Blepharospasm|Healthy Volunteers|Urinary Incontinence, Stress

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
2017-000642-22	2017-000642-22	P3	Active, not recruiting	Pelvic Pain\|Chronic Pain	2029-07-12		2022-03-13	Treatments
NCT04984317	NCT04984317	P1	Suspended	Urinary Incontinence, Stress	2026-12-01	4%	2026-01-27
NCT05512039	RELIEF	P2	Active, not recruiting	Overactive Bladder\|Urinary Incontinence, Urge	2026-09-01		2026-02-04
NCT06410859	HengLi009-Ⅱ	P2	Enrolling by invitation	Trigeminal Neuralgia	2026-06-30	12%	2024-05-14	Primary Endpoints\|Treatments
NCT06047444	C-BEOND	P3	Active, not recruiting	Migraine Disorders	2026-06-05	43%	2026-01-28	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date
NCT06794866	M24-697	P3	Active, not recruiting	Other	2026-04-01	56%	2025-08-15	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
2023-505810-12-00	M602011014	P3	Recruiting	Stroke\|Traumatic Brain Injury	2026-03-02		2025-05-02	Treatments
NCT07321834	AI-09-GL-201	P2	Active, not recruiting	Glabellar Reflex	2026-02-01	12%	2026-01-08	Primary Endpoints\|Treatments
NCT04075981	BOTAF	P3	Recruiting	Atrial Fibrillation	2025-10-30	20%	2025-05-17	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
NCT03848143	IIT-10247	P2	Completed	Neuropathic Pain\|Neuralgia	2025-06-30	2%	2025-08-05	Primary Endpoints\|Study Completion Date
CTR20243420	CTR20243420	P2	Completed	Muscle Spasticity	2025-06-09		2025-07-15	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT06091020	PaiNT	P2	Completed	Chronic Pain\|Neuralgia, Postherpetic\|Neuropathic Pain\|Peripheral Nerve Injuries	2025-05-07	12%	2025-07-25	Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
2023-503420-19-00	M602011072	P3	Completed	Cerebral Palsy	2025-03-04		2025-05-02	Treatments
NCT05216250	M21-471	P2	Completed	Essential Tremor	2025-02-03	12%	2025-03-06	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT05141006	IC/BPS POC	P2	Completed	Cystitis, Interstitial	2024-07-05	50%	2025-01-08	Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT06003049	COPD 101	P2	Completed	Chronic Obstructive Pulmonary Disease	2024-04-24	32%	2024-07-23	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
jRCT2051210082	jRCT2051210082	P3	Active, not recruiting	Sialorrhea	2024-03-31
2019-002461-35	2019-002461-35	P2	Active, not recruiting	Pancreatic Fistula	2021-07-07		2022-03-13	Treatments
2018-003231-30	BOTULINUM TOXIN IN PATIENTS WITH SPASTIC PARAPARESIA ASSOCIATED WITH ESCLEROSIS MULTIPLE	P3	Active, not recruiting	Multiple Sclerosis	2021-04-15		2022-03-13	Treatments
2016-000375-25	BotA-KKDS2016	P3	Active, not recruiting	Dyspareunia	2020-04-19		2022-03-13	Treatments
2016-005049-21	2016-005049-21	P2	Active, not recruiting	Paresis\|Cerebral Palsy\|Paraplegia	2016-10-20		2025-06-28	Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
2021-000240-22	2021-000240-22	P3	Active, not recruiting	Unknown	2034-05-24
NCT07210463	PLATINUM EU	P3	Recruiting	Other	2027-01-01	18%	2025-10-10	Primary Endpoints\|Treatments\|Trial Status
jRCT2061240117	jRCT2061240117	P3	Recruiting	Unknown	2026-11-30
NCT07122193	PLATINUM US	P3	Recruiting	Other	2026-10-01	52%	2025-08-30	Primary Endpoints\|Start Date

Recent News Events

Date	Type	Title
03/10/2026	News Article	The Aspen Group (TAG) Invests in the Future of Retail Healthcare, Reporting Strong 2025 Results
03/09/2026	News Article	JECT Opens Its Ninth Location in West Palm Beach
03/06/2026	News Article	Dermalogic Laser Center Launches New, Upgraded Website
03/05/2026	News Article	AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Onabotulinumtoxina